Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Atelectasis II: Pathophysiology01:10

Atelectasis II: Pathophysiology

Atelectasis develops when alveoli lose their air and collapse inward. Because lung tissue is naturally elastic, these air sacs shrink rather than remaining open. Collapsed alveoli are no longer ventilated, reducing their role in gas exchange. Blood flow may continue in these regions, creating a ventilation–perfusion mismatch. Clinical findings include decreased breath sounds, dullness to percussion, reduced chest expansion, and decreased tactile fremitus as sound transmission through collapsed...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England.

British journal of cancer·2021
Same author

Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

The British journal of dermatology·2019
Same author

Patient coping and expectations predict recovery after major orthopaedic trauma.

British journal of anaesthesia·2018
Same author

The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.

The British journal of dermatology·2018
Same author

Wound irrigation does not affect health-related quality of life after open fractures: results of a randomized controlled trial.

The bone & joint journal·2018
Same author

A historical review of the key bacterial and viral pathogens of Scottish wild fish.

Journal of fish diseases·2017
Same journal

Dr Archibald Hewan (1832-1883) and the University of Glasgow's medical libraries.

The journal of the Royal College of Physicians of Edinburgh·2025
Same journal

Joyce Grainger Learning Centre.

The journal of the Royal College of Physicians of Edinburgh·2025
Same journal

Features in this issue.

The journal of the Royal College of Physicians of Edinburgh·2025
Same journal

An unusual case of cutaneous tuberculosis and paradoxical TB in a patient with spondyloarthritis treated with adalimumab.

The journal of the Royal College of Physicians of Edinburgh·2025
Same journal

Leptospiral infection overlapping with autoimmune hepatitis: A diagnostic conundrum.

The journal of the Royal College of Physicians of Edinburgh·2025
Same journal

Tocilizumab vs bevacizumab in critically ill COVID-19 patients: Registry-based prospective study.

The journal of the Royal College of Physicians of Edinburgh·2025
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

Toxicities associated with bleomycin.

A J Fyfe1, P McKay

  • 1Gartnavel General Hospital, Glasgow, UK. andrew.fyfe@nhs.net

The Journal of the Royal College of Physicians of Edinburgh
|December 4, 2010
PubMed
Summary
This summary is machine-generated.

Bleomycin, an anti-cancer drug, can cause rare but serious skin and lung toxicity. Prompt recognition and treatment with drug withdrawal and steroids are crucial for managing these bleomycin side effects.

More Related Videos

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
02:46

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
05:45

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

Related Experiment Videos

Last Updated: Jun 6, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
02:46

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
05:45

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

Area of Science:

  • Oncology
  • Dermatology
  • Pulmonology

Background:

  • Bleomycin is a key chemotherapeutic agent for lymphomas and sarcomas.
  • It is also used for malignant effusions via chemical pleurodesis.
  • Bleomycin exhibits significant toxicity, primarily affecting the skin and lungs.

Observation:

  • Skin toxicity manifests as flagellate erythema, a distinctive whip-like rash.
  • Lung toxicity includes bleomycin-induced pneumonitis, which can be fatal.
  • These toxicities are considered uncommon in clinical practice, even in specialized centers.

Findings:

  • The study presents two cases of bleomycin-related toxicity.
  • It reviews current literature on bleomycin's dermatologic and pulmonary side effects.
  • Both flagellate erythema and pneumonitis typically resolve upon drug cessation and corticosteroid administration.

Implications:

  • Highlights the importance of recognizing rare bleomycin toxicities.
  • Emphasizes prompt management strategies including drug withdrawal and steroid therapy.
  • Contributes to the understanding of adverse events in cancer treatment and effusion management.